Wall Street analyst estimates for 908 Devices Inc. (MASS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable...
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.16 | ||
| 2026-08-11 | $-0.32 | $-0.14 | -125.4% |
| 2026-05-06 | $-0.22 | $-0.15 | -46.7% |
| 2026-03-03 | $-0.05 | $-0.06 | +16.7% |
| 2025-11-10 | $-0.15 | $-0.12 | -30.4% |
| 2025-08-05 | $-0.36 | $-0.16 | -125.0% |
| 2025-05-13 | $-0.22 | $-0.27 | +18.5% |
| 2025-03-04 | $-0.56 | $-0.35 | -60.0% |
Valuation Ratios
| Price / Book | 3.10 |
| EV / EBITDA | -11.15 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.1M | $18.0M | $26.9M | $42.2M | $46.9M | $50.2M | $59.6M | $56.2M |
| Cost of Revenue | $9.7M | $9.8M | $12.0M | $19.0M | $20.8M | $24.9M | $29.7M | $29.4M |
| Gross Profit | $12.4M | $8.1M | $14.9M | $23.2M | $26.0M | $25.3M | $29.9M | $26.8M |
| Research & Development | $9.5M | $9.0M | $8.2M | $13.1M | $17.5M | $21.9M | $25.5M | $13.8M |
| Selling, General & Admin | $9.3M | 0 | 0 | $32.2M | $43.9M | 0 | 0 | $37.2M |
| Operating Expenses | $18.8M | $20.3M | $20.7M | $45.3M | $61.4M | $68.1M | $106.6M | $51.0M |
| Operating Income | -$6.4M | -$12.1M | -$5.8M | -$22.1M | -$35.4M | -$42.8M | -$76.7M | -$24.2M |
| EBITDA | -$5.5M | -$11.2M | -$5.0M | -$20.8M | -$31.8M | -$40.3M | -$43.9M | -$28.9M |
| Interest Expense | $1.1M | $1.5M | $976000 | $486000 | $129000 | $201000 | 0 | 0 |
| Pre-tax Income | -$7.5M | -$13.4M | -$12.8M | -$22.2M | -$33.6M | -$36.6M | -$72.5M | -$33.3M |
| Income Tax | $50000 | 0 | 0 | 0 | 0 | -$211000 | -$282000 | -$66000 |
| Net Income | -$7.5M | -$13.4M | -$12.8M | -$22.2M | -$33.6M | -$36.4M | -$72.2M | -$36.6M |
| EPS | $-0.93 | $-2.02 | $-2.35 | $-0.79 | $-1.07 | $-1.13 | $-2.12 | $-1.01 |
| EPS (Diluted) | $-0.93 | $-2.02 | $-2.35 | $-0.79 | $-1.07 | $-1.13 | $-2.12 | $-0.94 |
| Shares Outstanding (Diluted) | $8.1M | $7.5M | $5.5M | $28.0M | $31.5M | $32.2M | $34.1M | $38.9M |
Price
| Price | $10.53 |
| Market Cap | $432M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACRS · CAPR · CERS · CVRX · NNOX · NPCE · QTRX
Explore sector: Healthcare · Medical - Specialties
More sections of MASS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks